| 1 |
High expression of SPP1 in patients with chronic obstructive pulmonary disease (COPD) is correlated with increased risk of lung cancer[J]. FEBS Open Bio, 2021, 11(4): 1237-1249.
|
| 2 |
中华医学会呼吸病学分会，中国肺癌防治联盟专家组. 肺结节诊治中国专家共识(2024年版)[J]. 中华结核和呼吸杂志，2024, 47(8): 716-729.
|
| 3 |
Uliński Robert, Kwiecień Iwona，Domagała-Kulawik Joanna. Domagała-Kulawik, Lung cancer in the course of COPD-Emerging problems today[J]. Cancers, 2022, 14(15): 3819.
|
| 4 |
Caramori G, Ruggeri P, Mumby S, et al. Molecular links between COPD and lung cancer: new targets for drug discovery？[J]. Expert Opin Ther Targets, 2019, 23(6): 539-553.
|
| 5 |
喻星豪，黄娜，刘罡. 肺癌的靶向与免疫联合治疗的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(2): 330-333.
|
| 6 |
田昊，赵彦程，胡洁，等. 肺癌合并慢性阻塞性肺疾病的免疫治疗研究进展[J]. 中华结核和呼吸杂志，2024, 47(1): 70-74.
|
| 7 |
Eshaq AM, Flanagan TW, Ba Abbad AA, et al. Immune checkpoint inhibitor-associated cutaneous adverse events: mechanisms of occurrence[J]. Int J Molecul Sci, 2024, 26(1): 88.
|
| 8 |
Martel J, Hanania HL, Patel AB. Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features[J]. Human Pathol, 2023, 140: 144-172.
|
| 9 |
田丹杏. 信迪利单抗致重度药疹[J]. 药物不良反应杂志，2022, 24(10): 554-556.
|
| 10 |
丁俊丽，赵静宇，徐乐臻，等. 免疫检查点抑制剂导致的免疫相关皮肤不良反应11例临床分析[J]. 实用皮肤病学杂志，2025, 18(4): 279-283.
|
| 11 |
杨艳利，宁亮，宋宝美. 特瑞普利单抗治疗相关性皮肤不良反应的护理[J]. 中西医结合护理(中英文), 2020, 6(6): 137-139.
|
| 12 |
Chitnis SD, Mortazavi A. Clinical guideline highlights for the hospitalist：Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy[J]. J Hospital Med, 2023, 18(11): 1013-1016.
|
| 13 |
Tier HL, Balogh EA, Bashyam AM, et al. Tolerability of and adherence to topical treatments in atopic dermatitis: a narrative review[J]. Dermatol Therapy, 2021, 11(2): 415-431.
|
| 14 |
中国医师协会皮肤科医师分会. 保湿润肤类产品应用指导专家共识(2023版)[J]. 中华皮肤科杂志，2023, 56(8): 711-717.
|
| 15 |
Heetfeld AB, Schill T, Schröder SS, et al. Challenging a paradigm: skin sensitivity to sodium lauryl sulfate is independent of atopic diathesis[J]. British J Dermatol, 2020, 183(1): 139-145.
|
| 16 |
杨智慧，罗园园，卢睿琦，等. 肿瘤免疫检查点抑制剂相关皮肤毒性管理的证据总结[J]. 护理学杂志，2024, 39(20): 46-50.
|
| 17 |
Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies[J]. J Am Academy Dermatol, 2023, 89(1): e1-e20.
|
| 18 |
刘旭，彭娟. 慢性创面渗液管理及收湿敛疮类外用中药的研究进展 [J]. 中医学，2025, 14(11): 5132-5140.
|
| 19 |
赵玉浩，蒋恩社，刘梦瑶，等. 含聚己双胍抗菌剂在慢性伤口治疗与护理中的应用研究进展[J]. 中华医院感染学杂志，2025, 35(21): 3355-3360.
|
| 20 |
Tran HQ, Shahriar SMS, Yan Z, et al. Recent advances in functional wound dressings[J]. Adv Wound Care, 2023, 12(7): 399-427.
|
| 21 |
Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials[J]. Clin Nutrit, 2003, 22(3): 321-336.
|
| 22 |
Almeida V, Pires D, Silva M, et al. Dermatological side effects of cancer treatment: psychosocial implications-a systematic review of the literature[J]. Healthcare (Basel), 2023, 11(19): 2621.
|
| 23 |
Annunziata MA, Muzzatti B, Bidoli E, et al. Hospital anxiety and depression scale (HADS) accuracy in cancer patients[J]. Support Care Cancer, 2020, 28(8): 3921-3926.
|
| 24 |
孙新星，王雅琳，吕望，等. 叙事护理对肺癌手术患者症状群管理及创伤后成长的应用研究[J]. 中国肺癌杂志，2025, 28(1): 40-46.
|
| 25 |
Xu H, Xu G, Liu Y, et al. Effect of narrative nursing intervention based on targeted nursing intervention on anxiety and nursing satisfaction of patients with malignant tumors undergoing chemotherapy[J]. J Healthcare Engineer, 2021, 2021: 4438446.
|
| 26 |
Zhang L, Han Q, Nan L, et al. Barriers and facilitators to narrative nursing implementation for junior nurses: A qualitative study[J]. Medicine, 2024, 103(40): e39922.
|
| 27 |
Biassoni F, Cassina G, Balzarotti S. Autobiographical narration as a tool for the empowerment of older adults′subjective and psychological wellbeing in nursing homes[J]. Clin Gerontol, 2019, 42(3): 334-343.
|
| 28 |
Berz AM, Bughad S, Vietti-Violi N, et al. Imaging assessment of toxicity related to immune checkpoint inhibitors[J]. Front Immunol, 2023, 14: 1133207.
|
| 29 |
中国临床肿瘤学会免疫治疗专家委员会，中国临床肿瘤学会抗肿瘤药物安全管理专家委员会. 免疫检查点抑制剂相关的毒性多学科诊疗协作组建设中国专家共识[J]. 临床肿瘤学杂志，2022, 27(2): 158-164.
|
| 30 |
《肿瘤免疫检查点抑制剂引起皮肤不良反应多学科专家共识(2025版)》编写委员会，上海200032, 杨骥. 肿瘤免疫检查点抑制剂引起皮肤不良反应多学科专家共识(2025版)[J]. 中国临床医学，2025, 32(2): 306-320.
|